Deep Medicine Acquisition Corp.
DMAQ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.03 | -0.00 |
| FCF Yield | 20.17% | -29.02% | -1.49% | -12.45% |
| EV / EBITDA | 1.04 | -0.01 | -27.88 | -2.34 |
| Quality | ||||
| ROIC | -8.18% | -7.87% | -9.71% | -10.26% |
| Gross Margin | 69.35% | 44.35% | 67.97% | 66.87% |
| Cash Conversion Ratio | 0.09 | 0.27 | 0.17 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | 634.51% | 648.86% | 3,342,836.09% | 3,173,670.69% |
| Free Cash Flow Growth | 244.78% | -20.15% | 88.03% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 5.02 | 1.13 | 0.02 | 0.02 |
| Interest Coverage | 10.28 | 1.23 | -0.83 | 0.17 |
| Efficiency | ||||
| Inventory Turnover | 0.47 | 0.89 | 0.45 | 3.08 |
| Cash Conversion Cycle | 39.43 | 26.45 | 93.61 | -0.09 |